BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 19077395)

  • 1. Do clinically insignificant tumors of the prostate exist?
    Stamatiou K; Alevizos A; Mariolis A; Spiliopoulou C; Alevizou A; Bovis K; Sofras F
    Urol Int; 2008; 81(4):379-82. PubMed ID: 19077395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
    Humphrey PA; Keetch DW; Smith DS; Shepherd DL; Catalona WJ
    J Urol; 1996 Mar; 155(3):816-20. PubMed ID: 8583583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
    Epstein JI; Walsh PC; Brendler CB
    J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
    Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
    Gosselaar C; Roobol MJ; Roemeling S; van der Kwast TH; Schröder FH
    Prostate; 2007 Feb; 67(2):154-61. PubMed ID: 17044079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of impalpable prostate adenocarcinoma and precancerous conditions in Greek male population: an autopsy study.
    Stamatiou K; Alevizos A; Perimeni D; Sofras F; Agapitos E
    Prostate Cancer Prostatic Dis; 2006; 9(1):45-9. PubMed ID: 16314890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
    Bastian PJ; Mangold LA; Epstein JI; Partin AW
    Cancer; 2004 Nov; 101(9):2001-5. PubMed ID: 15372478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: is there a difference?
    Pelzer AE; Colleselli D; Bektic J; Steiner E; Ramoner R; Mitterberger M; Schwentner C; Schaefer G; Ongarello S; Bartsch G; Horninger W
    BJU Int; 2008 Apr; 101(7):822-5. PubMed ID: 18261154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of prostate cancers detected at low PSA levels.
    Horninger W; Berger AP; Rogatsch H; Gschwendtner A; Steiner H; Niescher M; Klocker H; Bartsch G
    Prostate; 2004 Feb; 58(3):232-7. PubMed ID: 14743461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
    Epstein JI; Walsh PC; Carmichael M; Brendler CB
    JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.
    Stamatiou K; Alevizos A; Agapitos E; Sofras F
    Prostate; 2006 Sep; 66(12):1319-28. PubMed ID: 16688747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should men with serum prostate-specific antigen < or =4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review.
    Pepe P; Panella P; D'Arrigo L; Savoca F; Pennisi M; Aragona F
    Oncology; 2006; 70(2):81-9. PubMed ID: 16601365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Gosselaar C; Roobol MJ; Schröder FH
    BJU Int; 2005 Feb; 95(2):231-7. PubMed ID: 15667646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
    Konety BR; Bird VY; Deorah S; Dahmoush L
    J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy.
    Wolters T; Montironi R; Mazzucchelli R; Scarpelli M; Roobol MJ; van den Bergh RC; van Leeuwen PJ; Hoedemaeker RF; van Leenders GJ; Schröder FH; van der Kwast TH
    Prostate; 2012 Jan; 72(1):108-15. PubMed ID: 21538424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cancers detected at only a sextant or alternative location.
    Ochiai A; Troncoso P; Babaian RJ
    BJU Int; 2008 Apr; 101(7):837-40. PubMed ID: 18070187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease?
    Epstein JI
    Semin Urol Oncol; 1996 Aug; 14(3):165-73. PubMed ID: 8865479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.